About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 1NCT06997029

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Lead sponsor: Bristol-Myers Squibb•15 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com

CONTACT

855-907-3286 Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

CONTACT

Sponsors

Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants must be ≥ 18 years of age.
•Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy.
•Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
•Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1.
•For Part 2A only, participants must have CCNE1-amplified ovarian cancer

Exclusion Criteria

•Participants must not have an active brain metastasis.
•Participants must not have impaired cardiac function or clinically significant cardiac disease.
•Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months.
•Participants must not have Grade ≥ 2 peripheral neuropathy.

Related studies

RECRUITINGPhase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

RECRUITINGPhase 1/2

Study of SGN1 in Patients With Advanced Solid Tumor

NCT05038150 · Advanced Solid Tumor

RECRUITINGPhase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937 · Small Cell Lung Cancer, Melanoma, and more

RECRUITINGPhase 1

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT07181681 · Solid Tumors, Advanced Solid Tumor

RECRUITINGPhase 1/2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264 · Cancer, Colorectal Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 21, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE1

Enrollment234

Start dateAug 2025

Last updatedApr 21, 2026

Condition

Advanced Solid Tumor Advanced Breast Cancer Advanced Ovarian Cancer

Locations shown

University of Alabama at Birmingham

Birmingham, Alabama

Providence St. Jude Medical Center

Fullerton, California

Marin Cancer Care

Greenbrae, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 21, 2026Data synced to Clareo: May 16, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions